New Meds Set to Reshape US CNS and oncology Markets

CNS and cancer will be biopharma battlegrounds this year according to Clarivate Analytics, which says new meds will reshape the US market.

The US Food and Drug Administration (FDA) looks set to approve several innovative therapies for central nervous system (CNS) disorders and cancer in 2020 according to Clarivate.